Association of serum anti-Müllerian hormone and other factors with cumulative live birth rate following IVF

Hu, Kai-Lun; Liu, Fen-Ting; Xu, Huiyu; Li, Rong; Qiao, Jie

doi:10.1016/j.rbmo.2020.01.024

Cited by 21 publications

(26 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After controlling for the women’s age and the number of embryos replaced, both serum AMH and AFC were not significant independent predictors of live birth in the fresh IVF cycle nor cumulative live birth suggesting that their association with overall livebirth was through the number of oocytes and thereby number of embryos available to transfer. Another recent study in 9,494 Chinese women similarly demonstrated that increasing AMH up to 5–7 ng/ml predicted better cumulative live birth rate in IVF and that it was mainly through the association with oocyte yield ( 47 ).…”

Section: Initial Observationsmentioning

confidence: 92%

Clinical Application of AMH Measurement in Assisted Reproduction

Nelson

2020

Front. Endocrinol.

View full text Add to dashboard Cite

Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients.

show abstract

Section: Initial Observationsmentioning

confidence: 92%

Clinical Application of AMH Measurement in Assisted Reproduction

Nelson

2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…In women, a positive correlation between serum anti-Müllerian hormone and live birth rate following IVF has been described [29,30]. It is worth noting that the influence of maternal age and weight hamper the use of AMH concentration as the only parameter to predict IVF outcome in women.…”

Section: Discussionmentioning

confidence: 99%

“…In women, AMH measurements are used for many clinical applications, such as assessment of ovarian damage after therapy or estimation of the ovarian reserve in women suffering from polycystic ovary syndrome (PCOS) [27]. Moreover, the AMH concentration appears to be a good predictor of the oocyte quality [28] and has been positively associated with outcomes of in vitro fertilization, including live birth rates [29,30]. In cattle and goats, measurement of the circulating AMH concentration provides practical information to detect donors with the capacity to produce low or high numbers of in vivo embryos after super-ovulatory treatment [25,31,32].…”

Section: Introductionmentioning

confidence: 99%

Anti-Müllerian Hormone and OPU-ICSI Outcome in the Mare

Papas

Govaere

Peere

et al. 2021

Animals

View full text Add to dashboard Cite

Anti-Müllerian hormone (AMH) reflects the population of growing follicles and has been related to mammalian fertility. In the horse, clinical application of ovum pick-up and intracytoplasmic sperm injection (OPU-ICSI) is increasing, but results depend largely on the individuality of the mare. The aim of this study was to assess AMH as a predictor for the OPU-ICSI outcome in horses. Therefore, 103 mares with a total follicle count above 10 were included in a commercial OPU-ICSI session and serum AMH was determined using ELISA. Overall, the AMH level was significantly correlated with the number of aspirated follicles and the number of recovered oocytes (p < 0.001). Mares with a high AMH level (≥2.5 µg/L) yielded significantly greater numbers of follicles (22.9 ± 1.2), oocytes (13.5 ± 0.8), and blastocysts (2.1 ± 0.4) per OPU-ICSI session compared to mares with medium (1.5–2.5 µg/L) or low AMH levels (<1.5 µg/L), but no significant differences in blastocyst rates were observed. Yet, AMH levels were variable and 58% of the mares with low AMH also produced an embryo. In conclusion, measurement of serum AMH can be used to identify mares with higher chances of producing multiple in vitro embryos, but not as an independent predictor of successful OPU-ICSI in horses.

show abstract

“…However, these studies were all limited by their lack of evaluations of the cumulative live birth rate (CLBR), an indicator of ART success that has been highly recommended in recent years (12). Furthermore, these studies have evaluated the relationship between BMI and CLBR in females only (13) while paying little attention to the relationship between BMI and CLBR in males (14). Therefore, we aimed to evaluate the combined impact of female and male BMI on cumulative pregnancy outcomes after the first ovarian stimulation.…”

Section: Introductionmentioning

confidence: 99%

The Combined Impact of Female and Male Body Mass Index on Cumulative Pregnancy Outcomes After the First Ovarian Stimulation

Zhao

Jiang

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectivesTo evaluate the combined impact of male and female BMI on cumulative pregnancy outcomes after the first ovarian stimulation.DesignRetrospective cohort study.SettingUniversity-affiliated reproductive medicine center.PatientsA total of 15,972 couples undergoing their first ovarian stimulations from June 2009 to June 2016 were included. During the follow-up period between June 2009 and June 2018, 14,182 couples underwent a complete ART cycle involving fresh embryo transfer and subsequent frozen embryo transfers (FETs) after their first ovarian stimulations. Patients with a BMI <24 kg/m2 served as the reference group. Patients with a BMI ≥ 24 kg/m2 were considered to be overweight, and those with a BMI ≥28 kg/m2 were considered to be obese.Intervention(s)None.Primary Outcome MeasureThe primary outcome was the cumulative live birth rate (CLBR), which defined as the delivery of at least one live birth in the fresh or in the subsequent FET cycles after the first ovarian stimulation.ResultsIn the analyses of females and males separately, compared with the reference group, overweight and obese females had a reduced CLBR (aOR 0.83, 95% CI 0.7.92 and aOR 0.76, 95% CI 0.64–0.90). Similarly, overweight males had a reduced CLBR (aOR 0.91, 95% CI 0.83–0.99) compared with that of the reference group. In the analyses of couples, those in which the male was in the reference or overweight group and the female was overweight or obese had a significantly lower CLBR than those in which both the male and female had a BMI <24 kg/m2.ConclusionsThe CLBR is negatively impacted by increased BMI in the female and overweight status in the male, both individually and together.

show abstract

Association of serum anti-Müllerian hormone and other factors with cumulative live birth rate following IVF

Cited by 21 publications

References 25 publications

Clinical Application of AMH Measurement in Assisted Reproduction

Clinical Application of AMH Measurement in Assisted Reproduction

Anti-Müllerian Hormone and OPU-ICSI Outcome in the Mare

The Combined Impact of Female and Male Body Mass Index on Cumulative Pregnancy Outcomes After the First Ovarian Stimulation

Contact Info

Product

Resources

About